Revance Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, RVNC, Revance Therapeutics Inc, priceseries

Revance Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
15.19
Close
14.92
High
15.64
Low
14.88
Previous Close
15.25
Daily Price Gain
-0.33
YTD High
17.29
YTD High Date
Jan 3, 2022
YTD Low
11.65
YTD Low Date
Feb 24, 2022
YTD Price Change
-2.15
YTD Gain
-12.60%
52 Week High
33.83
52 Week High Date
Jul 9, 2021
52 Week Low
11.65
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-9.11
52 Week Gain
-37.91%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 16. 2016
17.95
Jan 12. 2017
21.84
17 Trading Days
21.66%
Link
LONG
May 25. 2017
21.25
Jun 12. 2017
23.64
11 Trading Days
11.23%
Link
LONG
Jun 16. 2017
23.95
Jul 10. 2017
26.05
15 Trading Days
8.76%
Link
LONG
Sep 25. 2017
25.10
Oct 9. 2017
27.22
10 Trading Days
8.43%
Link
LONG
Jun 17. 2019
11.32
Jul 2. 2019
12.23
11 Trading Days
8.01%
Link
LONG
Sep 9. 2019
11.27
Sep 26. 2019
13.68
13 Trading Days
21.36%
Link
LONG
Oct 14. 2019
14.02
Nov 5. 2019
14.95
16 Trading Days
6.62%
Link
LONG
Nov 15. 2019
15.81
Dec 4. 2019
17.22
12 Trading Days
8.91%
Link
LONG
Jan 7. 2020
16.34
Feb 11. 2020
23.84
24 Trading Days
45.88%
Link
LONG
Jun 17. 2020
22.58
Jun 30. 2020
24.60
9 Trading Days
8.95%
Link
LONG
Sep 11. 2020
28.15
Sep 21. 2020
30.01
6 Trading Days
6.59%
Link
LONG
Dec 10. 2020
24.83
Jan 4. 2021
27.56
15 Trading Days
10.99%
Link
LONG
Jun 8. 2021
29.01
Jun 25. 2021
30.84
13 Trading Days
6.32%
Link
LONG
Nov 30. 2021
13.68
Dec 29. 2021
16.67
20 Trading Days
21.87%
Link
Company Information
Stock Symbol
RVNC
Exchange
NasdaqGM
Company URL
http://www.revance.com
Company Phone
510-742-3400
CEO
L. Daniel Browne
Headquarters
California
Business Address
7555 GATEWAY BLVD., NEWARK, CA 94560
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001479290
About

Revance Therapeutics, Inc. is a clinical stage specialty biopharmaceutical company, which engages on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. It focuses on the development of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne in August 10, 1999 and is headquartered in Newark, CA.

Description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading